Decreased Expression of GLYATL1 Predicts Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma

References

• Linehan WM, Ricketts CJ. The cancer genome atlas of renal cell carcinoma: findings and clinical implications. Nat Rev Urol. 2019;16(9):539–552. doi:10.1038/s41585-019-0211-5
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. doi:10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Singh D. Current updates and future perspectives on the management of renal cell carcinoma. Life Sci. 2021;264:118632. doi:10.1016/j.lfs.2020.118632
   PubMed Web of Science ®Google Scholar
• Tacconi EMC, Tuthill M, Protheroe A. Review of adjuvant therapies in renal cell carcinoma: evidence to date. Onco Targets Ther. 2020;13:12301–12316. doi:10.2147/OTT.S174149
   PubMed Web of Science ®Google Scholar
• Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245–261. doi:10.1038/s41581-020-00359-2
   PubMed Web of Science ®Google Scholar
• Zhang H, Lang Q, Li J, et al. Molecular cloning and characterization of a novel human glycine-N-acyltransferase Gene GLYATL1, which activates transcriptional activity of HSE pathway. Int J Mol Sci. 2007;8(5):433–444.
   Web of Science ®Google Scholar
• Badenhorst CP, van der Sluis R, Erasmus E, van Dijk AA. Glycine conjugation: importance in metabolism, the role of glycine N-acyltransferase, and factors that influence interindividual variation. Expert Opin Drug Metab Toxicol. 2013;9(9):1139–1153. doi:10.1517/17425255.2013.796929
   PubMed Web of Science ®Google Scholar
• Eich ML, Chandrashekar DS, Rodriguez Pen AM, et al. Characterization of glycine-N-acyltransferase like 1 (GLYATL1) in prostate cancer. Prostate. 2019;79(14):1629–1639. doi:10.1002/pros.23887
   PubMed Web of Science ®Google Scholar
• Nalla AK, Williams TF, Collins CP, Rae DT, Trobridge GD. Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome. Mol Carcinog. 2016;55(11):1761–1771. doi:10.1002/mc.22425
   PubMed Web of Science ®Google Scholar
• Wang J, Shidfar A, Ivancic D, et al. Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer. Int J Cancer. 2017;140(11):2484–2497. doi:10.1002/ijc.30680
   PubMed Web of Science ®Google Scholar
• Guan R, Hong W, Huang J, et al. The expression and prognostic value of GLYATL1 and its potential role in hepatocellular carcinoma. J Gastrointest Oncol. 2020;11(6):1305–1321. doi:10.21037/jgo-20-186
   PubMed Web of Science ®Google Scholar
• Sun R, Li S, Zhao K, Diao M, Li L. Identification of ten core hub genes as potential biomarkers and treatment target for hepatoblastoma. Front Oncol. 2021;11:591507. doi:10.3389/fonc.2021.591507
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the xena platform. Nat Biotechnol. 2020;38(6):675–678. doi:10.1038/s41587-020-0546-8
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110. doi:10.1158/0008-5472.CAN-17-0307
   PubMed Web of Science ®Google Scholar
• Jiang H, Chen H, Wan P, Chen N. Decreased expression of HADH is related to poor prognosis and immune infiltration in kidney renal clear cell carcinoma. Genomics. 2021;113(6):3556–3564. doi:10.1016/j.ygeno.2021.08.008
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008;26(8):1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar
• Fenlon C, O’Grady L, Doherty ML, Dunnion J. A discussion of calibration techniques for evaluating binary and categorical predictive models. Prev Vet Med. 2018;149:107–114. doi:10.1016/j.prevetmed.2017.11.018
   PubMed Web of Science ®Google Scholar
• Longato E, Vettoretti M, Di Camillo B. A practical perspective on the concordance index for the evaluation and selection of prognostic time-to-event models. J Biomed Inform. 2020;108:103496. doi:10.1016/j.jbi.2020.103496
   PubMed Web of Science ®Google Scholar
• van der Sluis R, Badenhorst CP, Erasmus E, van Dyk E, van der Westhuizen FH, van Dijk AA. Conservation of the coding regions of the glycine N-acyltransferase gene further suggests that glycine conjugation is an essential detoxification pathway. Gene. 2015;571(1):126–134. doi:10.1016/j.gene.2015.06.081
   PubMed Web of Science ®Google Scholar
• Badenhorst CP, Erasmus E, van der Sluis R, Nortje C, van Dijk AA. A new perspective on the importance of glycine conjugation in the metabolism of aromatic acids. Drug Metab Rev. 2014;46(3):343–361. doi:10.3109/03602532.2014.908903
   PubMed Web of Science ®Google Scholar
• Amelio I, Cutruzzolá F, Antonov A, Agostini M, Melino G. Serine and glycine metabolism in cancer. Trends Biochem Sci. 2014;39(4):191–198. doi:10.1016/j.tibs.2014.02.004
   PubMed Web of Science ®Google Scholar
• Lino Cardenas CL, Bourgine J, Cauffiez C, et al. Genetic polymorphisms of glycine N-acyltransferase (GLYAT) in a French Caucasian population. Xenobiotica. 2010;40(12):853–861. doi:10.3109/00498254.2010.519407
   PubMed Web of Science ®Google Scholar
• Tian X, Wu L, Jiang M, et al. Downregulation of GLYAT facilitates tumor growth and metastasis and poor clinical outcomes through the PI3K/AKT/snail pathway in human breast cancer. Front Oncol. 2021;11:641399. doi:10.3389/fonc.2021.641399
   PubMedGoogle Scholar
• Bianchi C, Meregalli C, Bombelli S, et al. The glucose and lipid metabolism reprogramming is grade-dependent in clear cell renal cell carcinoma primary cultures and is targetable to modulate cell viability and proliferation. Oncotarget. 2017;8(69):113502–113515. doi:10.18632/oncotarget.23056
   PubMedGoogle Scholar
• Di Meo NA, Lasorsa F, Rutigliano M, et al. The dark side of lipid metabolism in prostate and renal carcinoma: novel insights into molecular diagnostic and biomarker discovery. Expert Rev Mol Diagn. 2023;23(4):297–313. doi:10.1080/14737159.2023.2195553
   PubMed Web of Science ®Google Scholar
• Lucarelli G, Rutigliano M, Loizzo D, et al. MUC1 tissue expression and its soluble form CA15-3 identify a clear cell renal cell carcinoma with distinct metabolic profile and poor clinical outcome. Int J Mol Sci. 2022;23(22):13968. doi:10.3390/ijms232213968
   PubMed Web of Science ®Google Scholar
• Vuong L, Kotecha RR, Voss MH, Hakimi AA. Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov. 2019;9(10):1349–1357. doi:10.1158/2159-8290.CD-19-0499
   PubMed Web of Science ®Google Scholar
• Tamma R, Rutigliano M, Lucarelli G, et al. Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment. Urol Oncol. 2019;37(6):355.e311–355.e319. doi:10.1016/j.urolonc.2019.01.025
   Web of Science ®Google Scholar
• Ghini V, Laera L, Fantechi B, et al. Metabolomics to assess response to immune checkpoint inhibitors in patients with non-small-cell lung cancer. Cancers. 2020;12(12):3574. doi:10.3390/cancers12123574
   PubMed Web of Science ®Google Scholar
• Corcoran SE, O’Neill LA. HIF1α and metabolic reprogramming in inflammation. J Clin Invest. 2016;126(10):3699–3707. doi:10.1172/JCI84431
   PubMed Web of Science ®Google Scholar
• Denk D, Greten FR. Inflammation: the incubator of the tumor microenvironment. Trends Cancer. 2022;8(11):901–914. doi:10.1016/j.trecan.2022.07.002
   PubMed Web of Science ®Google Scholar
• Lin H, Fu L, Li P, et al. Fatty acids metabolism affects the therapeutic effect of anti-PD-1/PD-L1 in tumor immune microenvironment in clear cell renal cell carcinoma. J Transl Med. 2023;21(1):343. doi:10.1186/s12967-023-04161-z
   PubMed Web of Science ®Google Scholar
• Jeffries KA, Dempsey DR, Farrell EK, et al. Glycine N-acyltransferase-like 3 is responsible for long-chain N-acylglycine formation in N18TG2 cells. J Lipid Res. 2016;57(5):781–790. doi:10.1194/jlr.M062042
   PubMed Web of Science ®Google Scholar
• Waluk DP, Schultz N, Hunt MC. Identification of glycine N-acyltransferase-like 2 (GLYATL2) as a transferase that produces N-acyl glycines in humans. FASEB J. 2010;24(8):2795–2803. doi:10.1096/fj.09-148551
   PubMed Web of Science ®Google Scholar